

The SPEAKER pro tempore. The gentleman from Arizona has 15 minutes remaining.

Mr. BIGGS. Mr. Speaker, in closing, I want to mention how I came to really be converted to the cause of right to try.

I served in the Arizona State Legislature with Laura Knaperek, who was also serving in the legislature when I first met her. By 2014, she was no longer serving in the State legislature. She was an advocate. That year, Laura was in the fight of her life against ovarian cancer, and her mission was to see right-to-try legislation passed into law.

In the end, her efforts for this cause succeeded beyond everyone's wildest expectations when 80 percent of the electorate in Arizona voted to enact right to try. But, unfortunately, Laura is not with us because she lost her brave battle with cancer last year. Her legacy as a tireless patient advocate lives on.

I will continue to carry on the fight not just for Laura Knaperek, but for all those patients across this country who are battling against the odds every day.

I am joined by those who are here tonight, those who have cosponsored this bill, and many other advocacy groups, such as the Goldwater Institute in Arizona that continues to fight for this.

I fight for Bertrand Might. Bertrand is a very special little boy. He was the first person ever to be diagnosed with a rare, fatal genetic disorder called NGLY1 that has left this 7-year-old paralyzed. Because the disease was only identified by scientists in 2012 and only a few people worldwide have been diagnosed with it, there is no cure and no treatment available. Because the disorder is so rare, a drug may never be developed to treat it.

But scientists have found that Bertrand responds to certain investigational therapies. So Bertrand's family will have to rely on trying those new investigational medications as long as they have access to them. That is why we need this right-to-try legislation.

I fight for Jordan McLinn. Seven-year-old Jordan says he wants to grow up to be a firefighter so he can save lives. He has Duchenne muscular dystrophy, which could leave him paralyzed within 5 years and shortens his life expectancy to only 20 years. There is a drug now being used in clinical trials that is helping young people like Jordan, but it could take another 7 years for that drug to be available on the market. His parents cannot afford to wait for the FDA to give that drug its final approval. He could be in a wheelchair by then. This investigational drug could add years to Jordan's life, which would give him the chance to save others.

We have already heard, when Representative FITZPATRICK discussed Matt Bellina, his needs and his advocacy. We fight for him, and we fight for Mikaela Knapp.

At 24, Mikaela was diagnosed with a deadly form of kidney cancer that had already migrated into her bones before she even knew she was sick. She went through every known treatment in a matter of months and nothing worked. Her high school sweetheart, Keith, heard about a drug under development that was successfully treating people with this same cancer, but Mikaela was not allowed to enroll in the clinical trial. Mikaela and Keith launched a social media campaign to try to get access to the drug, but it wasn't enough. The FDA didn't help.

Mikaela died on April 24, 2014. Five months later, on September 4, the FDA gave final approval to the drug that might have saved her.

I fight for Diego Morris. When he was 10 years old, Diego woke up with a sore leg that his mom thought was just another sports injury, but the pain didn't go away. They knew something was wrong, but they never expected osteosarcoma, a rare form of bone cancer.

After exhausting all treatments available, Diego's doctors recommended he try mifamurtide, which wasn't available in the United States but was being safely used and had been given the Prix Galien Award, the gold medal for pharmaceutical development in England. The Morris family wasted no time and made the move abroad to try to save Diego's life. The treatments worked. Now Diego is back home in Phoenix and back to playing his favorite sports.

We fight unitedly for the countless other patients who deserve a right to try. We must act without further delay. Again, I thank those who have been here to testify tonight.

Mr. Speaker, I yield back the balance of my time.

ENROLLED BILL SIGNED

Karen L. Haas, Clerk of the House, reported and found truly enrolled a bill of the House of the following title, which was thereupon signed by the Speaker:

H.R. 1329. An act to increase, effective as of December 1, 2017, the rates of compensation for veterans with service-connected disabilities and the rates of dependency and indemnity compensation for the survivors of certain disabled veterans, and for other purposes.

ADJOURNMENT

Mr. BIGGS. Mr. Speaker, I move that the House do now adjourn.

The motion was agreed to; accordingly (at 9 o'clock and 14 minutes p.m.), under its previous order, the House adjourned until tomorrow, Thursday, November 2, 2017, at 10 a.m. for morning-hour debate.

EXECUTIVE COMMUNICATIONS, ETC.

Under clause 2 of rule XIV, executive communications were taken from the Speaker's table and referred as follows:

3031. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's withdrawal of direct final rule—National Emission Standards for Hazardous Air Pollutants for Wool Fiberglass Manufacturing; Flame Attenuation Lines [EPA-HQ-OAR-2010-1042; FRL-9770-08-OAR] (RIN: 2060-AT58) received October 20, 2017, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on Energy and Commerce.

3032. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's direct final rule—Voluntary Consensus Standards Update; Formaldehyde Emission Standards for Composite Wood Products [EPA-HQ-OPPT-2017-0245; FRL-9962-84] (RIN: 2070-AK36) received October 20, 2017, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on Energy and Commerce.

3033. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's direct final rule—Approval and Promulgation of State Air Quality Plans for Designated Facilities and Pollutants; City of Philadelphia; Control of Emissions from Existing Sewage Sludge Incineration Units [EPA-R03-OAR-2017-0509; FRL-9969-92-Region 3] received October 20, 2017, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on Energy and Commerce.

3034. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's direct final rule—Approval and Promulgation of Air Quality Implementation Plans; Pennsylvania; Pennsylvania's Adoption of Control Techniques Guidelines for Automobile and Light-Duty Truck Assembly Coatings [EPA-R03-OAR-2017-0342; FRL-9969-83-Region 3] received October 20, 2017, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on Energy and Commerce.

3035. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's direct final rule—Air Plan Approval; Wisconsin; 2017 revisions to NR 400 and 406 [EPA-R05-OAR-2017-0280; FRL-9969-89-Region 5] received October 20, 2017, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on Energy and Commerce.

3036. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's direct final rule—Air Plan Approval; Illinois; Volatile Organic Compounds Definition [EPA-R05-OAR-2017-0323; FRL-9970-17-Region 5] received October 25, 2017, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on Energy and Commerce.

3037. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's final rule—National Emission Standards for Hazardous Air Pollutants: Publicly Owned Treatment Works Residual Risk and Technology Review [EPA-HQ-OAR-2016-0490; FRL-9969-95-OAR] (RIN: 2060-AS85) received October 20, 2017, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on Energy and Commerce.

3038. A letter from the Director, Regulatory Management Division, Environmental Protection Agency, transmitting the Agency's final rule—Determination of Attainment by the Attainment Date for the 2008 Ozone Standard; Philadelphia-Wilmington-Atlantic City, PA-NJ-MD-DE Nonattainment